Community-Based Accompaniment Mitigates Predictors of Negative Outcomes for Adults on Antiretroviral Therapy in Rural Rwanda

AIDS and Behavior

Volumn 20, Issue 5, 2016, Pages 1009-1016

  Gupta, Neil ^a,b   Munyaburanga, Christian ^a,c   Mutagoma, Mwumvaneza ^d   Niyigena, John W ^a   Kayigamba, Felix ^e   Franke, Molly F ^f   Hedt Gauthier, Bethany ^a,f  

^a PARTNERS IN HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF RWANDA   (Rwanda)

^d RWANDA BIOMEDICAL CENTER   (Rwanda)

^e Ministry of Health   (Rwanda)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adherence; Antiretroviral therapy; Community based accompaniment; Rwanda; Virologic suppression

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; FEMALE; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; PSYCHOLOGY; RURAL POPULATION; RWANDA; SOCIAL SUPPORT; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RURAL POPULATION; RWANDA; SOCIAL SUPPORT; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84940914656     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-015-1185-9     Document Type: Article

References (46)

1. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to 3 years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1–15.
2. Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10:155–66.
3. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:2039–64.
4. Joint United Nations Program on HIV/AIDS (UNAIDS). The gap report. Geneva: Joint United Nations Program on HIV/AIDS; 2014.
5. Decroo T, Rasschaert F, Telfer B, Remartinez D, Laga M, Ford N. Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. Int Health. 2013;5:169–79.
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
7. Franke MF, Kaigamba F, Socci AR, Hakizamungu M, Patel A, Bagiruwigize E, et al. Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda. Clin Infect Dis. 2013;56:1319–26.
8. Muñoz M, Finnegan K, Zeladita J, Caldas A, Sanchez E, Callacna M, et al. Community-based DOT-HAART accompaniment in an urban resource-poor setting. AIDS Behav. 2010;14:721–30.
9. Thomson DR, Rich ML, Kaigamba F, Socci AR, Hakizamungu M, Bagiruwigize E, et al. Community-based accompaniment and psychosocial health outcomes in HIV-infected adults in Rwanda: a prospective study. AIDS Behav. 2014;18:368–80.
10. National Institute of Statistics Rwanda. Census and housing report. Kigali: National Institute of Statistics; 2012.
11. The Republic of Rwanda. Economic development and poverty reduction strategy: 2013–2018. Kigali: Republic of Rwanda; 2013.
12. The Ministry of Health of Rwanda. Third health system strategic plan III: July 2012–June 2018. Kigali: Rwanda Ministry of Health; 2012.
13. Logia DE, Rowson M, Ndagije F. Innovations in Rwanda’s health system: looking to the future. Lancet. 2008;372:256–61.
14. Ministry of Health of Rwanda, National Institute of Statistics of Rwanda and IFC Macro. Rwanda demographic and health survey 2010. Calverton, MD: MOH, NISR, and IFC Macro; 2011.
15. Rwanda Biomedical Center. Annual report: July 2010–June 2011. Kigali: Rwanda Biomedical Center; 2012.
16. Rwanda Ministry of Health. Guide pour la Prise en Charge Therapeutique du VIH/SIDA. Kigali: Rwanda Ministry of Health; 2005.
17. Rich ML, Miller AC, Niyigena P, Franke MF, Niyonzima JB, Socci A, et al. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J Acquir Immune Defic Syndr. 2012;59:e35–42.
18. Merkel E, Gupta N, Nyirimana A, Niyonsenga SP, Nahimana E, Stulac S, et al. Clinical outcomes among HIV-positive adolescents attending an integrated and comprehensive adolescent-focused HIV care program in rural Rwanda. J HIV AIDS Soc Serv. 2013;12:437–50.
19. Epino HM, Rich ML, Kaigamba F, Hakizamungu M, Socci A, Bagiruwigize E, et al. Reliability and construct validity of three health-related self-report scales in HIV-positive adults in rural Rwanda. AIDS Care. 2012;24:1576–83.
20. Broadhead WE, Gehlbach SH, de Gruy FV, Kaplan BH. The Duke-UNC Functional Social Support Questionnaire: measurement of social support in family medicine patients. Med Care. 1988;26:709–23.
21. Coates J, Swindale A, Bilinsky P. Household food insecurity access scale (HFIAS) for measurement of household food access: indicator guide (v. 3). Washington, D.C.: Food and Nutrition Technical Assistance Project, Academy for Educational Development; 2007.
22. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, D.C.: Department of Health and Human Services; 2011.
23. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Debis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–29.
24. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, Monforte AD, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002;185:178–87.
25. May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449–57.
26. Kabore I, Bloem J, Etheredge G, Obiero W, Wanless S, Doykos P, et al. The effect of community-based support services on clinical efficacy and health-related quality of life in HIV/AIDS patients in resource-limited settings in sub-Saharan Africa. AIDS Patient Care STDS. 2010;24:581–94.
27. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M, et al. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011;11:942–51.
28. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238–44.
29. Taiwo BO, Idoko JA, Welty LJ, Ihedinachi O, Job G, Iyaji PG, et al. Assessing the virologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2010;54:85–92.
30. Stubbs BA, Micek MA, Pfeiffer JT, Montoya P, Gloyd S. Treatment partners and adherence to HAART in central Mozambique. AIDS Care. 2009;21:1412–9.
31. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S, et al. Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr. 2008;48:611–9.
32. Chang LW, Kagaayi J, Nakigozi G, Ssemijja V, Packer AH, Serwadda D, et al. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS ONE. 2010;5:e10923.
33. Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010;24:1273–80.
34. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492–8.
35. Posse M, Baltussen R. Barriers to access to antiretroviral treatment in Mozambique, as perceived by patients and health workers in urban and rural settings. AIDS Patient Care STDS. 2009;23:867–75.
36. Mshana GH, Wamoyi J, Busza J, Zaba B, Changalucha J, Kaluvya S, et al. Barriers to accessing antiretroviral therapy in Kisses, Tanzania: a qualitative study of early rural referrals to the national program. AIDS Patient Care STDS. 2006;20:649–57.
37. Dlamini PS, Wantland D, Makoae LN, Chirwa M, Kohi TW, Greeff M, et al. HIV stigma and missed medications in HIV-positive people in five African countries. AIDS Patient Care STDS. 2009;23:377–87.
38. Shin S, Muñoz M, Zeladita J, Slavin S, Caldas A, Sanchez E, et al. How does directly observed therapy work? The mechanisms and impact of a comprehensive directly observed therapy intervention of highly active antiretroviral therapy in Peru. Health Soc Care Community. 2011;19:261–71.
39. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis. 2004;38:S429–36.
40. Williams AB, Fennie KP, Bova CA, Burgess JD, Danvers KA, Dieckhaus KD. Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial. J Acquir Immune Defic Syndr. 2006;42:314–21.
41. Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43:S123–6.
42. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6:e11.
43. O’Laughlin KN, Wyatt MA, Kaaya S, Bangsberg DR, Ware NC. How treatment partners help: social analysis of an African adherence support intervention. AIDS Behav. 2012;16:1308–15.
44. Dhillon RS, Bonds MH, Fraden M, Ndahiro D, Ruxin J. The impact of reducing financial barriers on utilisation of a primary health care facility in Rwanda. Glob Public Health. 2012;7:71–86.
45. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–65.
46. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34:281–8.